Company Overview
Snapshot
Founded in July 2021 by Abraham Domb, GentaGel operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its slow-release antibiotic treatment.
Business overview
GentaGel is a Health Tech & Life Sciences company specializing in pharmaceutical and medical biotechnology, specifically drug delivery. The company develops a local slow-release antibiotic treatment, GentaGel-LR, designed to be injected and continuously release antibiotics for up to 60 days. This technology aims to provide effective antibiotic treatment in the administered area, avoiding systemic side effects and reducing healthcare costs. GentaGel serves the healthcare and life sciences markets, targeting providers and the medical devices industry with its innovative medical products.
Log in to access full profile ›Company Intelligence Q&A
- What is GentaGel's core product?
- GentaGel's core product is GentaGel-LR, a local slow-release antibiotic treatment designed to continuously release antibiotics for up to 60 days after injection, targeting treatment and prevention of surgical site infections.
- When was GentaGel founded?
- GentaGel was founded in July 2021.
- Who is a co-founder of GentaGel?
- Abraham Domb is a co-founder of GentaGel.
- What is the primary sector of GentaGel?
- GentaGel's primary sector is Health Tech & Life Sciences, with a focus on Pharma & Medical Biotechnology and Drug Delivery.
- What is the current product stage of GentaGel-LR?
- GentaGel-LR is currently in the Clinical Trial product stage, indicating it is undergoing testing in humans to evaluate its safety and efficacy.